FindTrial
Sign In

Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07036809
Enrollment
90
Registered
2025-06-25
Start date
2023-06-01
Completion date
2025-10-01
Last updated
2026-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Leukemia

Keywords

acute leukemia, Antithrombin III, protein C, Protein S, D Dimer

Brief summary

The goal of this observational study is to evaluate the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Leukemia (Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)). The main questions it aims to answer are: What are the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Lymphoblastic Leukemia? What are the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Myeloid Leukemia? Researchers will compare patients with Acute Leukemia (30 with ALL and 30 with AML) to 30 healthy control subjects to see if there are significant differences in the levels of Antithrombin III, Protein C, Protein S, and D-dimer. Participants will: Undergo full history and clinical examination. Have routine hematological analysis including Complete Blood Count (CBC), blood film, Erythrocyte sedimentation rate (ESR), Prothrombin Time Test and INR (PT/INR), and partial thromboplastin time (PTT). Have specific tests for quantitative measurement of Antithrombin III, Protein C, Protein S, and D-dimer. Undergo Flow cytometry immunophenotyping.

Interventions

DIAGNOSTIC_TESTAntithrombin III

quantitative measurement(%)

DIAGNOSTIC_TESTProtein C

quantitative measurement(%)

DIAGNOSTIC_TESTProtein S

quantitative measurement(%)

DIAGNOSTIC_TESTD-dimer

quantitative measurement( ug/ml)

DIAGNOSTIC_TESTFlow cytometry immunophenotyping

Flow cytometry immunophenotyping

Sponsors

Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

1. patients with leukemia in group 1 and 2. 2. willing to participate in the study.

Exclusion criteria

1. refusing to participate. 2. patients with know to have either hereditary thrombophilia or current thrombosis.

Design outcomes

Primary

MeasureTime frameDescription
Assessment of Antithrombin III, Protein C, Protein S, and D-dimer Levels in Acute Leukemia Patientsat the time of patient recruitment for the study.To evaluate and compare the quantitative levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients diagnosed with Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) against healthy control subjects. This assessment will help determine any significant differences in these coagulation parameters within the different acute leukemia subtypes and in comparison to healthy individuals.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026